Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$89.25 USD

89.25
440,887

+0.37 (0.42%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $89.27 +0.02 (0.02%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

by Zacks Equity Research

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect

by Zacks Equity Research

Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.

How Should You Play Centene (CNC) Ahead of Q1 Earnings?

by Zacks Equity Research

Centene's (CNC) first-quarter earnings are likely to reflect significant growth in commercial marketplace membership.

TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.

TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

by Zacks Equity Research

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

TransMedics (TMDX) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?

by Zacks Equity Research

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why TransMedics (TMDX) Stock Might be a Great Pick

by Zacks Equity Research

TransMedics (TMDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Here's What Key Metrics Tell Us About TransMedics (TMDX) Q3 Earnings

by Zacks Equity Research

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.